Gil M. Labrucherie
Gil M. Labrucherie's purchase track record
How the stock did after each of Gil M. Labrucherie's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/27/2025 | SEPN | $22K | +70.0% | +111.7% | +10.9% |
| 2/19/2025 | SEPN | $207K | +63.2% | +99.8% | +4.1% |
| 5/4/2022 | RZLT | $200K | -15.9% | -56.0% | -12.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Septerna Schedules Upcoming Investor Conference Appearances. Septerna announced plans to participate in upcoming investor conferences. Such events are routine for publicly traded companies and provide opportunities for management to engage with institutional investors and analysts. The conferences may include presentations and one-on-one meetings, though no specific details about agenda topics were disclosed.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
NKTR receives mixed analyst coverage and pipeline focus. Several research firms started coverage on Nektar Therapeutics this week. UBS began coverage with a neutral rating and a $53 price target, while Leerink issued an outperform rating and set a $130 target, and Raymond James launched coverage with a market‑perform view. BTIG kept a buy rating with a $178 target. At the same time, commentary pieces note the company's pipeline progress and recent rezpegaldesleukin data, suggesting potential long‑term value and possible undervaluation.
Transaction History
| RZLT | ▲ Buy | Grant | 21,000 | $0 | 11/19/2025 | View on chart |
| RZLT | ▲ Buy | Grant | 9,000 | $0 | 6/10/2025 | View on chart |
| SEPN | ▲ Buy | Open Market | 3,718 | $22K | 2/27/2025 | View on chart |
| SEPN | ▲ Buy | Open Market | 6,282 | $35K | 2/25/2025 | View on chart |
| SEPN | ▲ Buy | Open Market | 5,000 | $29K | 2/21/2025 | View on chart |
| SEPN | ▲ Buy | Open Market | 14,500 | $85K | 2/20/2025 | View on chart |
| SEPN | ▲ Buy | Open Market | 10,500 | $58K | 2/19/2025 | View on chart |
| RZLT | ▲ Buy | Grant | 25,500 | $0 | 2/16/2025 | View on chart |
| NKTR | ▼ Sell | Open Market | 17,448 | $69K | 5/16/2022 | View on chart |
| NKTR | ▲ Buy | Grant | 28,750 | $0 | 5/15/2022 | View on chart |
| RZLT | ▲ Buy | Open Market | 52,631 | $200K | 5/4/2022 | View on chart |
| NKTR | ▼ Sell | Open Market | 7,579 | $83K | 2/16/2022 | View on chart |
| NKTR | ▲ Buy | Grant | 52,950 | $0 | 12/16/2021 | View on chart |
| NKTR | ▼ Sell | Open Market | 3,000 | $38K | 11/18/2021 | View on chart |
| NKTR | ▼ Sell | Open Market | 21,149 | $278K | 11/16/2021 | View on chart |
| NKTR | ▲ Buy | Grant | 40,150 | $0 | 11/15/2021 | View on chart |
| NKTR | ▼ Sell | Open Market | 3,000 | $41K | 8/17/2021 | View on chart |
| NKTR | ▼ Sell | Open Market | 7,867 | $109K | 8/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Rezolute Q4 EPS Misses Estimates, Reports Fiscal 2026 Results
Rezolute reported fourth-quarter and full-year fiscal 2026 financial results, with an EPS of $(0.20) missing the expected $(0.15). The company also provided a business update alongside these figures. The stock is currently trading near its support level, reflecting the market's reaction to the earnings miss.
Rezolute Q4 EPS Misses Estimates, Reports Fiscal 2026 Results. Rezolute reported fourth-quarter and full-year fiscal 2026 financial results, with an EPS of $(0.20) missing the expected $(0.15). The company also provided a business update alongside these figures. The stock is currently trading near its support level, reflecting the market's reaction to the earnings miss.